定量蛋白质组学技术在阿尔茨海默症临床标志物遴选中的研究进展

发布时间：2018-05-05 04:10

本文选题：定量蛋白质组学 + 阿尔茨海默症　；参考：《中国科学:化学》2014年05期

【摘要】：阿尔茨海默症(Alzheimer’s disease,AD)是一种以行为功能紊乱、神经元逐渐丢失为主要特征的退行性疾病,它对人类的生活质量和生命造成了极大威胁.随着临床标志物(clinical biomarker)概念的提出和定量蛋白质组学的研究进展,对于促进AD病诊断、监测疾病进程以及评估现有治疗手段等方面提出了新的思路,但临床标志物的遴选存在许多技术难点.定量蛋白质组学利用其能够快速分析和准确鉴定疾病中功能蛋白的特点,大大提高了遴选临床标志物的效率.本文综述了定量蛋白质组学技术在遴选AD中临床标志物的应用进展.
[Abstract]:Alzheimer's disease (AD) is a degenerative disease characterized by behavioral disorder and neuron loss, which poses a great threat to the quality of life and life of human beings. With the concept of clinical biomarker and the research progress of quantitative proteomics, new ideas have been put forward to promote the diagnosis of AD disease, monitor the disease process and evaluate the existing treatment methods. However, there are many technical difficulties in the selection of clinical markers. Quantitative proteomics can rapidly analyze and accurately identify the characteristics of functional proteins in diseases, which greatly improves the efficiency of selecting clinical markers. This article reviews the application of quantitative proteomics in the selection of clinical markers in AD.
【作者单位】：蛋白质与植物基因研究国家重点实验室;北京大学生命科学学院;
【基金】：国家自然科学基金(31270872) 国家重大研究计划(2010CB912203,2011CB915504)的资助
【分类号】：R749.16;Q51-3

【共引文献】